おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Lyndra Therapeutics
company
About
Lyndra Therapeutics is a novel technology platform reinventing medicine for a healthier world.
- 101 - 250
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $60.90M
- Industries
- Biotechnology,Clinical Trials,Health Care,Pharmaceutical
- Founded date
- Jan 14, 2015
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Lyndra Therapeutics is reinventing medicines to make daily pills a thing of the past, replacing them with its oral, ultra-long-acting, sustained-release therapies. Administering and conveniently distributing medicines in weekly or longer-term doses – including using polypill approaches – will improve safety, efficacy, and adherence to maximize global health impact and lower overall healthcare costs.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$144.40M
Lyndra Therapeutics has raised a total of
$144.40M
in funding over 2 rounds. Their latest funding was raised on
Jun 24, 2021 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 24, 2021 | Series C | $60.50M | 1 | — | — | Detail |
| Feb 11, 2019 | Series B | $60.90M | 3 | — | — | Detail |
| Apr 13, 2017 | Series A | $23M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
3
Lyndra Therapeutics is funded by 3 investors.
HOPU Investment Management Company
and Orient Life
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series C |
|
|
— | Series B |
|
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
